ArchiveNovember 2018

Advent Calender 2018

It’s december again, but the “House of Mouse” has closed its doors again (for 2019) So how can we fill 25 days for an advent calender for some Christmas Fun. After a bit of head scratching….I thought Maybe we could look at the World’s best selling drug. This is glatiramer acetate….. but how does it work? The Regulators say it “Targets the mechansism...

The logic of GA

Eskyte I, Manzano A, Pepper G, Pavitt S, Ford H, Bekker H, Chataway J, Schmierer K, Meads D, Webb E, Potrata B. Understanding treatment decisions from the perspective of people with relapsing remitting multiple Sclerosis: A critical interpretive synthesis.Mult Scler Relat Disord. 2018 Nov 17;27:370-377. doi: 10.1016/j.msard.2018.11.016. BACKGROUND: Multiple Sclerosis (MS) is a chronic...

Lipoic Acid in SPMS

Loy BD, Fling BW, Horak FB, Bourdette DN, Spain RI.Complement Ther Med. 2018;41:169-174.Effects of lipoic acid on walking performance, gait, and balance in secondary progressive multiple sclerosis. BACKGROUND: Gait and balance impairment is common in secondary progressive multiple sclerosis (SPMS). Lipoic acid (LA), an over-the-counter antioxidant, is effective in MS animal models and may improve...

Symptomatic drugs may slow your progression

Drugs that  control MS symtoms have been reported to be neuroprotective in models of MS and so they should slow progression.   I say NSS this is what we have been saying for a long time, Hundehege P, Fernandez-Orth J, Römer P, Ruck T, Müntefering T, Eichler S, Cerina M, Epping L, Albrecht S, Menke AF, Birkner K, Göbel K, Budde T, Zipp F, Wiendl H, Gorji A, Bittner S, Meuth SG.Targeting...

A sneak peak at the blog’s makeover. What do you think?

The Bart-MS blog is getting a brand new makeover. And we want to hear your thoughts about it. Why the change? We listened to some common problems from our readers and talked about what was and wasn’t working for authors and guest bloggers too. Here are the main things we came up with: It’s too difficult to find past posts. You have to rely on the search function. The search function...

Have a heart

Acta Neurol Belg. 2018 Nov 23. doi: 10.1007/s13760-018-1051-4. [Epub ahead of print] Adrenergic hyperactivity: a missing link between multiple sclerosis and cardiovascular comorbidities? Habek M, Mutak T, Nevajdić B, Pucić D, Crnošija L, Krbot Skorić M. Abstract The aim of the study is to investigate differences in non-standard adrenergic baroreflex sensitivity (BRS) indices in patients with...

Learning about the effects of B cell depletion

B cell depletion in other conditions, can it tells us how things work D’Amico E, Zanghì A, Chisari CG, Fermo SL, Toscano S, Arena S, Patti F, Zappia M. Effectiveness and safety of Rituximab in demyelinating diseases spectrum: An Italian experience.Mult Scler Relat Disord. 2018 Oct 3;27:324-326. doi: 10.1016/j.msard.2018.09.041. [Epub ahead of print] BACKGROUND: Rituximab (RTX), a monoclonal...

S1P2 receptor as a target for remyelination

People have desperately being trying to show that fingolimod promotes remyelination and it has been have notably suggested that it can target glial cells via sphingosine -1-phosphate 5 receptor (S1P-5) adding to the effects on modulation of S1P1 to blcok lymphocyte migration. Fingolimod blocks activity of S1P1, S1P3, S1P4 and S1P5, is the missing activity on S1P2 a probablem… Maybe so...

Watch out when you finish fingo

Anyone who reads the blog will know about this already, but just in case it stipped your mind…When you decide to start a new treatment, you need to think how you will tcome off it, if it doesn’t work. The big problem comes with the immune-migration inhibitors and they cause rebound if disease is not effectiviely controlled These are natalizumab that traps cells in the blood and...

Translate

Categories

Recent Posts

Recent Comments

Archives